ArticleActa medica Lituanica2026
Changes in NR2ab Antibody Levels in the Blood of Patients Depending on their Condition: Acute or Chronic Cerebral Ischaemia.
Article in Acta medica Lituanica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The study aimed to determine the efficacy of antibodies to the NR2ab subunits of the N-methyl-D-aspartate (NMDA) receptor (NR2ab) as a biomarker for the differential diagnosis of acute and chronic cerebral ischaemia (CCI) among patients in Kazakhstan. Materials and methods: The study involved 52 patients with CCI classified as second-degree according to the Fazekas scale and 47 patients with acute ischaemic stroke (AIS), rated at 16-20 on the National Institutes of Health Stroke Scale (NIHSS), who were hospitalised in stroke centres within 24 hours of the first symptoms of stroke and confirmed by magnetic resonance imaging. Serum samples were collected to determine NR2ab antibody levels. Results: The results of the study showed that the mean level of NR2ab in patients with CCI was 1.42 ng/ml (95% CI: 1.2-1.6), while in patients with AIS it was 1.99 ng/ml (95% CI: 1.7-2.3). Statistical analysis revealed a significant difference between the groups ( Conclusions: The results confirm that determining the level of NR2ab can be a useful tool for a timely diagnosis and selection of adequate treatment, especially in conditions of limited access to neuroimaging. Incorporation of this method into the standard diagnostic process can improve the efficiency of detecting ischaemic disorders and optimise patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.